DSSG Group: Genitourinary

Prostate Cancer being Treated with Stereotactic Body Radiotherapy

To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.

For Patients who previously participated in the BP-007 clinical study

The main purpose of this post marketing clinical follow up is to assess late toxicity and quality of life in subjects who participated in BP-007 clinical study.

Metastatic Castrate Resistant Prostate Cancer (mCRPC).

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC).

Advanced Renal Cell Carcinoma (RCC) with clear cell component after prior therapy

This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.

Advanced or Metastatic Clear-Cell Renal Cell Carcinoma (RCC) Who Have Received Prior Anti-Angiogenic Therapy

The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of Subcutaneous Nivolumab versus Intravenous Nivolumab in participants with previously treated clear cell renal cell carcinoma that is advanced or has spread.

High-Risk Muscle-Invasive Bladder Cancer Who are ctDNA Positive Following Cystectomy (IMvigor011)

The purpose of this trial is to evaluate the efficacy and safety of adjuvant treatment with Atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy.

Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy

The purpose of this study is to assess the efficacy and safety of oral Belzutifan (MK-6482) plus intravenous (IV) Pembrolizumab (MK-3475) compared to placebo plus Pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy.

Metastatic or Locally Advanced Unresectable Urothelial Cancer

The primary objective of this study is to assess overall survival (OS) with Sacituzumab Govitecan-hziy in comparison with treatment of physician’s choice (TPC) in participants with metastatic or locally advanced unresectable urothelial cancer (UC).

Either very high-risk localised prostate cancer, or very high risk features with PSA persistence or rise within one year following radical prostatectomy, suitable for Radiotherapy.

Determine the effectiveness of adding Darolutamide to androgen deprivation therapy (ADT) and radiation therapy in either the primary definitive setting or very high risk postoperative setting.

Metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC)

The purpose of this study is to create an international, population-based,
prospective registry of minimum 5,000 men with advanced prostate cancer.